Medigene AG, an immuno-oncology platform company focused on the discovery and development of differentiated T cell immunotherapies for solid tumors, and BioNTech SE have announced that their collaboration to advance T cell receptor (TCR) immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in February 2022.   In February 2022, Medigene and BioNTech entered into a global multi-target collaboration to discover and develop T cell r...